Evidence map›Paper›PMID 34916293›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors.

Eunna Huh, Jonathan Gallion, Melina A Agosto, Sara J Wright, Theodore G Wensel, Olivier Lichtarge

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Eunna HuhDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0001-9328-7474
Jonathan GallionDepartment of Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX 77030.
Melina A AgostoVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030.
Sara J WrightVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030.
Theodore G WenselVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0003-3518-9352
Olivier LichtargeDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030; lichtarge@bcm.edu.ORCID 0000-0003-4057-7122
Baylor College of Medicine · USDalhousie University · CA

Funding

Functional Determinnats in G Protein-coupled ReceptorsR01GM066099 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2003 to 2022
$7.5M
A Knowledge Map to Find Alzheimer's Disease DrugsR01AG061105 · NIA · BAYLOR COLLEGE OF MEDICINE · PI LICHTARGE, OLIVIER · 2018 to 2022
$4.6M
NIA NIH HHS R01 AG061105NIGMS NIH HHS R01 GM066099
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) are the largest family of human proteins. They have a common structure and, signaling through a much smaller set of G proteins, arrestins, and effectors, activate downstream pathways that often modulate hallmark mechanisms of cancer. Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling similarly so as to favor a tumor. We hypothesized that somatic mutations in tumor samples may not be enriched within a single gene but rather that cognate mutations with similar effects on GPCR function are distributed across many receptors. To test this possibility, we systematically aggregated somatic cancer mutations across class A GPCRs and found a nonrandom distribution of positions with variant amino acid residues. Individual cancer types were enriched for highly impactful, recurrent mutations at selected cognate positions of known functional motifs. We also discovered that no single receptor drives this pattern, but rather multiple receptors contain amino acid substitutions at a few cognate positions. Phenotypic characterization suggests these mutations induce perturbation of G protein activation and/or β-arrestin recruitment. These data suggest that recurrent impactful oncogenic mutations perturb different GPCRs to subvert signaling and promote tumor growth or survival. The possibility that multiple different GPCRs could moonlight as drivers or enablers of a given cancer through mutations located at cognate positions across GPCR paralogs opens a window into cancer mechanisms and potential approaches to therapeutics.

Indexed as

beta-ArrestinsCalciumCell Line, TumorComputer SimulationEnzyme-Linked Immunosorbent AssayGene Expression Regulation, NeoplasticHumansMutationNeoplasmsProtein ConformationReceptors, G-Protein-Coupledbeta-ArrestinsCalciumReceptors, G-Protein-Coupledcancerevolutionary action (EA)G protein-coupled receptor (GPCR)mutational signaturesβ-arrestin

Identifiers

PMID34916293
PMCPMC8713800
OpenAlexW4200140974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.